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reviewing how the use of a structured model for emotions can improve PRO instru-
ment development by strengthening the role of emotions during CE. Methods: 
A literature review of CE with emotional motivations was undertaken to iden-
tify the most salient aspects for PRO instrument development. Results: The 
method for eliciting emotional motivations is based on motivation research and 
extraction techniques (see Forbes, 2010) containing, nine distinct categories of 
emotional motivation. The CE protocol relies upon neuroscience research (see 
Damasio 2010) which points to the power of a sub-800 millisecond response frame 
for eliciting purely emotional reactions to stimuli. Images validated in large sam-
ple research as uniquely evoking one of the nine motivational emotions are the 
stimuli for this emotional evocation procedure. This augmentation to typical CE 
has been used repeatedly to identify needs for emotional health among suffer-
ers of diabetes, arthritis, and heart disease – in each case linking evocations to 
absence of needed emotional energies that could promote self-care and disease 
recovery. ConClusions: CE techniques for most PRO development do not allow 
investigators to sufficiently understand the patient experiences of physical symp-
toms, effect of ADLs, and the emotional consequences of a disease or condition of 
interest. Adding emotional motivation techniques to CEs will broaden our ability 
to capture the emotional experiences of patients so that related PRO instrument 
items may better represent the experiences of patients’ suffering from various 
medical conditions.
PIH63
Inadequate treatment of Post-surgIcal PaIn may result In extended 
HosPItalIzatIon PerIod
Ferreira CN1, Santana CF1, Rufino CS1, PaloniEd 2, Paiva EC2, Fahham L3, Ribeiro AP1, 
Mazza DD4
1Pfizer, São Paulo, Brazil, 2Orizon, Barueri, Brazil, 3Sense Company, São Paulo, Brazil, 
4Universidade Federal de São Paulo, São Paulo, Brazil
objeCtives: Demonstrate through a retrospective analysis of secondary data, 
that patients with inadequate treatment of post-surgical appendectomy and colic 
renal pain may end up having a longer period of hospitalization. Methods: A 
retrospective administrative claims database containing over 18 millions lives from 
Brazilian private hospitals (ORIZON database), was assessed (from January through 
June 2014), of patients who underwent a surgical intervention by appendectomy 
(n= 1,618) or who had an episode of renal colic and nefretic syndrome (n= 6,555) 
identified by International Codes Disease (N20, N21, N22, N23) and who received 
one of the nonsteroidal anti-inflammatory drugs (NSAIDs) available in the market 
(parecoxib, tenoxicam, and ketoprofen, ketorolac) for pain treatment. After patient 
identification, the average period of hospital permanence was assessed by drug 
group. . Median time differences between groups were assessed thru Kruskal-Wallis 
method. A significance level of 5% was adopted. All statistical analysis were per-
forme in R, version 3.1.1. Results: The average period of hospital permanence 
for the appendectomy procedure was 2.20 days (medical calculations from private 
hospitals round it to 3 days) group of (tenoxicam, ketoprofen, ketorolac) versus 1.95 
(p= 0.006) in the parecoxib, respectively. In the episodes of renal colic, we had 33 
hours versus 25 hours (p < 0.001) in the group of (tenoxicam, ketoprofen, ketorolac) 
versus (parecoxib), respectively. ConClusions: Pain is the one of the critical signs 
in clinical evolution, quality care and outcome disease. The period of hospital per-
manence after surgery or during renal colic or nefretic syndrome treatment is the 
utmost importance and implies in hospital costs. The longer patients stay in hospi-
tal higher is the probability of clinical complication, delaying treatment and some 
cases to increase mortality. The adequate treatment may reduce hospital stay and 
improve assistance as well as financial results
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objeCtives: To evaluate the Satisfaction with life among general population 
of Pakistan. Methods: A cross sectional, descriptive study was undertaken 
with study population responding to internet survey, living all over Pakistan. 
Satisfaction with life was assessed using Ed diener SWLS scale. Descriptive analy-
sis was used to elaborate people’s demographic characteristics while inferential 
statistics were applied to report the association among study variables. Results: 
Out of 2203 questionnaires filled 1507 were from Pakistan. Gender distribution was 
761 (50.5%) males. Most popular age group of study participants was 20-25 years 
(46.6%) with 340 (22.6%) married and 669 (44.4%) having graduate level education. 
Overall 460 (30.5%) participants were satisfied with their lives and 190 (12.6%) were 
extremely satisfied from their lives. One hundred and sixty seven (11.1%) and 38 
(2.5%) participants were dissatisfied and extremely dissatisfied from their lives 
respectively. Age and marital status had no association with satisfaction of life. 
Profession is one factor in dissatisfaction towards life. People in urban locality have 
positive trend of satisfaction when compared with the rural ones. ConClusions: 
This study provides baseline assessment for the Satisfaction with life of general 
population of Pakistan and the results could be applied in clinical practice. The 
study revealed the impact of the following conditions on the various satisfac-
tion with life domains measured: Education, work, personal income & Locality. 
Overall the percentage of Pakistani people who are satisfied with their life (67.6%) 
is more as compared to the percentage of dissatisfied people. Satisfaction with 
life of general populationof pakistan could be further improved if better job and 
education opportunitiesare provided.
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outside the abdomen, or nothing at all. Participants most commonly circled at least 
one portion of the middle (89.8%) and/or lower (92.2%) abdomen. 205 participants 
(49.9%) circled the median and lower abdomen only. 73 participants (17.8%) circled 
an area inclusive of at least a portion of all nine regions of the abdomen; of these 
participants, 28 (38.4%) had a self-reported history of disease(s) with abdominal symp-
toms (e.g., irritable bowel syndrome, GERD). ConClusions: Despite relatively low 
education levels and low prevalence of diseases with abdominal symptoms, nearly 
all participants demonstrated knowledge of the general location of the abdomen. 
However, the data suggest that nearly half of participants were considering the middle 
and lower regions of the abdomen exclusively. Therefore, to obtain accurate reports of 
symptoms pertaining to a specific abdominal location, it would behoove instrument 
developers to define and identify (e.g., through an illustration), the precise anatomical 
area of interest, which should improve the reliability and validity of the PRO measure.
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objeCtives: Clinical trials for diabetes treatment are increasingly collecting elec-
tronic patient-reported outcomes (ePRO) and physiological measurements outside 
of the clinical setting. This study examined the usability of a handheld ePRO device 
and glucometer as an integrated system for collecting, transmitting, and character-
izing blood glucose readings. Methods: Twelve subjects with type 2 diabetes were 
interviewed in the U.S. Subjects were given a handheld ePRO device (LogPad LW), 
synthetic glucose solution, and a Bluetooth-enabled MyGlucoHealth meter with 
test strips. Subjects were asked to take a glucose reading, transmit the reading to 
the handheld device, and characterize the glucose value in a diary. Interviewers 
observed subjects and conducted semi-structured interviews to determine usability 
of the devices and integration step. Results: Subjects were 47 to 67 years old and 
55% female. No major difficulties were observed by the interviewers. 100% of sub-
jects found the exercise to be easy, and easily understood how to take a glucose read-
ing, transmit it to a handheld device and to characterize the glucose reading. 75% 
of subjects reported that they would not be bothered by the size of the devices. All 
subjects (100%) reported they were willing and able to carry both devices with them 
and complete a diary outside of the home, and 88% of subjects would be willing to 
use both devices in public. When asked about additional features on the integrated 
system, 57% stated it would be helpful to review their most recent blood glucose 
readings on the handheld device, and 71% would like the ability to turn a reminder 
alarm on or off. ConClusions: An integrated handheld ePRO/glucometer system 
was found to be easy to use and acceptable to subjects with type 2 diabetes, and 
is a feasible solution for collecting, transmitting and characterizing blood glucose 
readings outside of the clinical setting.
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objeCtives: To enable researchers to better understand the regulatory require-
ments for inclusion of patient-reported outcome (PRO) measures as efficacy end-
points for the development and approval of drugs for generic pain and analgesic 
indications, plus three pain-related diseases (i.e., migraines, rheumatoid arthritis 
[RA], and systemic lupus erythematosus [SLE]). This research reviews, contrasts, 
and compares the European Medicines Agency (EMA) and US Food and Drug 
Administration (FDA) medical guidelines in these conditions. Methods: A targeted 
search was conducted for recent (2010-2015) European and US medical guidelines in 
the conditions mentioned. Information pertaining to PROs within these guidelines 
was extracted and compared. Attention was paid to similarities, differences, and 
gaps across these guidelines. Results: Both EMA and FDA consistently recom-
mend the use or development of reliable and valid measures across all disease 
areas and emphasized the importance of measuring symptoms from the patient 
perspective. For example, both authorities recommend the assessment of intensity 
for pain and analgesic indications; assessment of migraine-associated symptoms 
(nausea, vomiting, photophobia, phonophobia) for migraine treatment efficacy; 
and measurement of fatigue and other relevant symptoms for patients with SLE. 
For RA, the EMA recommends assessment of pain intensity through the use of a 
PRO measure. More often, EMA guidelines emphasize the requirement of assessing 
health-related quality of life (HRQoL) or functioning through PRO measures. This 
is not to say that HRQoL is not addressed by FDA guidelines (e.g., measurement of 
physical and emotional function and HRQoL in pain, assessment of physical func-
tion in RA); however, examples of specific assessments are more prominent within 
EMA guidelines. In contrast, FDA guidelines are more specific regarding how best to 
evaluate disease symptoms. ConClusions: While similarities between EMA and 
FDA medical guidelines exist, variations between guidelines highlight the need for 
sponsors to become familiar with and incorporate these guidelines early on in the 
drug development process.
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objeCtives: FDA guidance for PROs has led to an increased reliance on qualita-
tive methodologies to identify relevant domains for instrument development. 
Concept elicitation (CE), which underpins the development of PRO instruments, 
often relies on exploring patient experience through the lens of the patient as it 
relates to disease burden and the impact on activities of daily living. Yet the deeper 
emotional experience of patients is missed. We address this gap in methodology by 
